Daratumumab is the first of several anti-CD38 monoclonal antibody-based therapeutics that improve anti-tumor immunity and also demonstrate an inhibitory effect on AML mitochondrial transfer in vitro and in vivo (Farber et al., 2018; Mistry et al., 2019). The gene discussed is CD38; the disease is neoplasm.